Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
Rhea-AI Summary
Milestone Scientific (NYSE: MLSS) announced preliminary, unaudited Q2 2026 revenue of approximately $2.8M, up about 21% YoY, and 1H 2026 revenue of about $5.0M, up 9% YoY.
The medical segment is expected to deliver 300% revenue growth versus Q2 2025, supported by progress in reimbursement claims, while international dental markets continue to expand. Final Q2 2026 results are expected in August 2026.
Positive
- Preliminary Q2 2026 revenue ~$2.8M, approximately 21% higher than Q2 2025
- Preliminary 1H 2026 revenue ~$5.0M, about 9% higher than 1H 2025
- Base business expected to contribute ~$2.4M of Q2 2026 revenue
- Around $0.5M Q2 2026 upside from international orders
- Medical segment revenue expected to grow 300% versus Q2 2025
- 100 reimbursement claims submitted and first paid workers’ compensation claim
- Dental business gains approval in Uzbekistan, with registrations planned in Japan, Mexico, Turkey, India
Negative
- All Q2 and 1H 2026 figures are preliminary, unaudited and may change after closing procedures
- Medical business is growing from a small revenue base
- More meaningful revenue contributions are expected later in 2026 rather than immediately
News Market Reaction – MLSS
In the Jul 1 session, MLSS gained 9.19%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -2.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Governance changes | Positive | +3.9% | Board refresh and restructured founder agreement to support next growth phase. |
| May 27 | Clinical adoption update | Positive | +3.5% | Study-backed evidence of CompuFlo adoption with reduced complications in procedures. |
| May 14 | Quarterly earnings | Neutral | -4.3% | Mixed Q1 results with flat revenue, narrower loss and ongoing going‑concern risk. |
| May 07 | Earnings call notice | Neutral | -2.6% | Scheduling details for Q1 2026 results and business update conference call. |
| May 07 | Medical business expansion | Positive | +16.3% | Expanded CompuFlo medical program across payers and geographies with new advisors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MLSS has typically reacted positively to operational and clinical updates, with governance and product adoption news drawing upside moves and only a conference‑call scheduling release showing divergence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Medical Segment Momentum Accelerates, Posting
Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and ASPN Co-Founder and Vice Chairman, Dr. Dawood Sayed
ROSELAND, N.J., July 01, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter ending June 30, 2026.
The Company expects total revenue of approximately
Eric Hines, Chief Executive Officer of Milestone Scientific, stated, “We are highly encouraged by our preliminary second-quarter top-line results, which reflect both the continued execution of our core business initiatives and the successful penetration of key international markets. Our base business performed exceptionally well and is expected to contribute approximately
Mr. Hines continued, “Importantly, our medical segment continues to build steady momentum. We expect our medical segment to achieve
“Our positive results reflect the strategic vision and rigorous execution of our management team and newly refreshed board of directors. As an example of this synergy, we will be showcasing our technology at the upcoming American Society of Pain & Neuroscience (ASPN) Conference in Miami Beach from July 16–18, alongside our Board Member and ASPN Co-Founder, Dr. Dawood Sayed. By aligning our leadership's extensive expertise with our core business objectives, we have fundamentally shifted the Company's momentum. As commercialization initiatives continue to scale over the coming quarters, we expect more meaningful revenue contributions later in the year, and remain fiercely committed to disciplined operational execution.”
Dr. Dawood Sayed Vice Chairman and Co-Founder, ASPN, welcomes attendees to this year’s meeting, “ASPN continues to bring together the brightest minds in pain medicine to advance evidence-based care through innovation, collaboration, and education. Our 2026 meeting theme, ‘Where Intelligence Meets Human Insight,’ reflects our commitment to integrating emerging technologies with the clinical judgment and expertise that ultimately improve patient outcomes. We look forward to welcoming colleagues from around the world to Miami for an exceptional scientific program and meaningful collaboration.”
Preliminary Financial Data
The anticipated financial results discussed in this press release are preliminary, unaudited and represent the most current information available to management. The Company’s actual financial results for the second quarter ended June 30, 2026, are subject to the completion of the Company’s financial closing procedures and may differ materially from these preliminary estimates. The Company expects to release its full financial results and host a conference call in August 2026.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, future success and other statements that are forward-looking in nature. These statements involve known and unknown risks, uncertainties and other factors that may cause Milestone's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such factors include, but are not limited to, our ability to maintain our listing on the NYSE American, our ability to achieve our strategic and operational objectives, our ability to continue as a going concern, our ability to successfully commercialize our products, the impact of global economic and geopolitical conditions, and other factors detailed in our Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Milestone undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Hayden IR:
James Carbonara
(646)-755-7412
james@haydenir.com
Brett Maas
(646) 536-7331
brett@haydenir.com
